Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Paromomycin topical - Appili Therapeutics

Next Previous
X
Search
Drug Profile

Paromomycin topical - Appili Therapeutics

Alternative Names: ATI-1801; WR-279-396

Latest Information Update: 01 Jul 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Department of defence; US Army Medical Research and Development Command
  • Developer Department of defence
  • Class Aminoglycosides; Anthelmintics; Antibacterials; Antiprotozoals; Oligosaccharides; Small molecules
  • Mechanism of Action Protein 30S ribosomal subunit inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Cutaneous leishmaniasis
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase III Cutaneous leishmaniasis

Most Recent Events

  • 11 Aug 2023 Appili Therapeutics plans to request meeting with the US FDA to discuss phase III data and planned NDA submission, in 2023
  • 23 Jun 2023 Appili Therapeutics plans for priority review voucher for ATI 1801
  • 28 Feb 2023 Chemical structure information added

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top